Citadel Advisors’s Ibere Pharmaceuticals Warrants IBER.WS Stock Holding History
Bought
Maintained
Sold
Other funds holding IBER.WS
DMKJ
Citadel Advisors's IBER.WS Position: Q4 2022 in Review
Citadel Advisors sold out of Ibere Pharmaceuticals Warrants (IBER.WS) in Q4 2022, closing a stake of 48,449 shares — an estimated $4K sold.
Citadel Advisors first reported a position in IBER.WS in Q2 2021 and held it in 6 quarters. The position peaked at $230K in Q3 2021. 33 funds tracked by Wall St. Rank hold IBER.WS as of Q4 2022.
- Citadel Advisors reported no remaining Ibere Pharmaceuticals Warrants position as of Q4 2022 after selling out during the quarter.
- Citadel Advisors sold 48,449 Ibere Pharmaceuticals Warrants shares in Q4 2022, an estimated $4K.
- Citadel Advisors first reported a position in Ibere Pharmaceuticals Warrants in Q2 2021 and held it in 6 quarters.
- Citadel Advisors's Ibere Pharmaceuticals Warrants position peaked at $230K in Q3 2021.
- 33 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Warrants as of Q4 2022.
Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.